{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T01:23:55Z","timestamp":1792632235950,"version":"4.5.0"},"reference-count":31,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,12,16]],"date-time":"2021-12-16T00:00:00Z","timestamp":1639612800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100010269","name":"Wellcome Trust","doi-asserted-by":"publisher","award":["207472\/Z\/17\/Z"],"award-info":[{"award-number":["207472\/Z\/17\/Z"]}],"id":[{"id":"10.13039\/100010269","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["aaojournal.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Ophthalmology"],"published-print":{"date-parts":[[2022,5]]},"DOI":"10.1016\/j.ophtha.2021.12.004","type":"journal-article","created":{"date-parts":[[2021,12,8]],"date-time":"2021-12-08T20:29:00Z","timestamp":1638995340000},"page":"530-541","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":26,"title":["Topical Chlorhexidine 0.2% versus Topical Natamycin 5% for the Treatment of Fungal Keratitis in Nepal"],"prefix":"10.1016","volume":"129","author":[{"given":"Jeremy J.","family":"Hoffman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reena","family":"Yadav","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandip D.","family":"Sanyam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5213-4383","authenticated-orcid":false,"given":"Pankaj","family":"Chaudhary","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abhishek","family":"Roshan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanjay K.","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanjay K.","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sailesh K.","family":"Mishra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon","family":"Arunga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victor H.","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2371-5709","authenticated-orcid":false,"given":"David","family":"Macleod","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9251-2318","authenticated-orcid":false,"given":"Astrid","family":"Leck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew J.","family":"Burton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ophtha.2021.12.004_bib1","first-page":"273","article-title":"Mycotic keratitis\u2014a global\u00a0threat from the filamentous fungi","volume":"7","author":"Hoffman","year":"2021","journal-title":"J\u00a0Fungi (Basel)"},{"key":"10.1016\/j.ophtha.2021.12.004_bib2","doi-asserted-by":"crossref","first-page":"e49","DOI":"10.1016\/S1473-3099(20)30448-5","article-title":"The global incidence and diagnosis of fungal keratitis","volume":"21","author":"Brown","year":"2021","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.ophtha.2021.12.004_bib3","first-page":"264","article-title":"Epidemiological features and laboratory results of bacterial and fungal keratitis: a five-year study at a rural tertiary-care hospital in western Maharashtra, India","volume":"53","author":"Deorukhkar","year":"2012","journal-title":"Singapore Med J"},{"key":"10.1016\/j.ophtha.2021.12.004_bib4","doi-asserted-by":"crossref","first-page":"158","DOI":"10.3109\/09286586.2011.595041","article-title":"Microbial keratitis in East Africa: why are the outcomes so poor?","volume":"18","author":"Burton","year":"2011","journal-title":"Ophthalmic Epidemiol"},{"key":"10.1016\/j.ophtha.2021.12.004_bib5","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1080\/09286586.2019.1616775","article-title":"Delay along the care seeking journey of patients with microbial keratitis in Uganda","volume":"26","author":"Arunga","year":"2019","journal-title":"Ophthalmic Epidemiol"},{"key":"10.1016\/j.ophtha.2021.12.004_bib6","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1080\/09286586.2019.1682619","article-title":"Risk factors of microbial keratitis in Uganda: a case control study","volume":"27","author":"Arunga","year":"2020","journal-title":"Ophthalmic Epidemiol"},{"key":"10.1016\/j.ophtha.2021.12.004_bib7","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1001\/jamaophthalmol.2013.1497","article-title":"The mycotic ulcer treatment trial: a randomized trial comparing natamycin vs voriconazole","volume":"131","author":"Prajna","year":"2013","journal-title":"JAMA Ophthalmol"},{"key":"10.1016\/j.ophtha.2021.12.004_bib8","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1001\/archophthalmol.2010.102","article-title":"Comparison of natamycin and voriconazole for the treatment of fungal keratitis","volume":"128","author":"Prajna","year":"2010","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.ophtha.2021.12.004_bib9","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1111\/j.1442-9071.2010.02473.x","article-title":"Voriconazole versus natamycin as primary treatment in fungal corneal ulcers","volume":"39","author":"Arora","year":"2011","journal-title":"Clin Exp Ophthalmol"},{"key":"10.1016\/j.ophtha.2021.12.004_bib10","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1136\/bjophthalmol-2014-306485","article-title":"Re-appraisal of topical 1% voriconazole and 5% natamycin in the treatment of fungal keratitis in a randomised trial","volume":"99","author":"Sharma","year":"2015","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.ophtha.2021.12.004_bib11","first-page":"CD004241","article-title":"Medical interventions for fungal keratitis","volume":"4","author":"FlorCruz","year":"2015","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.ophtha.2021.12.004_bib12","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1001\/jamaophthalmol.2016.4096","article-title":"Effect of Oral Voriconazole on Fungal Keratitis in the Mycotic Ulcer Treatment Trial II (MUTT II): a randomized clinical trial","volume":"134","author":"Prajna","year":"2016","journal-title":"JAMA Ophthalmol"},{"key":"10.1016\/j.ophtha.2021.12.004_bib13","series-title":"World Health Organization Model List of Essential Medicines, 21st List, 2019","year":"2019"},{"key":"10.1016\/j.ophtha.2021.12.004_bib14","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1128\/CMR.12.1.147","article-title":"Antiseptics and disinfectants: activity, action, and resistance","volume":"12","author":"McDonnell","year":"1999","journal-title":"Clin Microbiol Rev"},{"key":"10.1016\/j.ophtha.2021.12.004_bib15","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/j.ajo.2016.05.021","article-title":"Altered patterns of fungal keratitis at a London ophthalmic referral hospital: an eight-year retrospective observational study","volume":"168","author":"Ong","year":"2016","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.ophtha.2021.12.004_bib16","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/j.ajo.2009.06.009","article-title":"Acanthamoeba keratitis: diagnosis and treatment update 2009","volume":"148","author":"Dart","year":"2009","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.ophtha.2021.12.004_bib17","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1007\/BF00130925","article-title":"Mycotic keratitis: susceptibility to antiseptic agents","volume":"19","author":"Martin","year":"1995","journal-title":"Int Ophthalmol"},{"key":"10.1016\/j.ophtha.2021.12.004_bib18","doi-asserted-by":"crossref","first-page":"141","DOI":"10.3109\/09286589709115721","article-title":"Trial of chlorhexidine gluconate for fungal corneal ulcers","volume":"4","author":"Rahman","year":"1997","journal-title":"Ophthalmic Epidemiol"},{"key":"10.1016\/j.ophtha.2021.12.004_bib19","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1136\/bjo.82.8.919","article-title":"Randomised trial of 0.2% chlorhexidine gluconate and 2.5% natamycin for fungal keratitis in Bangladesh","volume":"82","author":"Rahman","year":"1998","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.ophtha.2021.12.004_bib20","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2020-038066","article-title":"Topical chlorhexidine 0.2% versus topical natamycin 5% for fungal keratitis in Nepal: rationale and design of a randomised controlled non-inferiority trial","volume":"10","author":"Hoffman","year":"2020","journal-title":"BMJ Open"},{"key":"10.1016\/j.ophtha.2021.12.004_bib21","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/S0197-2456(99)00031-8","article-title":"The Age-Related Eye Disease Study (AREDS): design implications. AREDS report no. 1","volume":"20","year":"1999","journal-title":"Control Clin Trials"},{"key":"10.1016\/j.ophtha.2021.12.004_bib22","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1001\/jamaophthalmol.2015.1468","article-title":"Development and Validation of a Smartphone-Based Visual Acuity Test (Peek Acuity) for Clinical Practice and Community-Based Fieldwork","volume":"133","author":"Bastawrous","year":"2015","journal-title":"JAMA Ophthalmol"},{"key":"10.1016\/j.ophtha.2021.12.004_bib23","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.1016\/S0161-6420(94)31087-6","article-title":"Herpetic Eye Disease Study. A controlled trial of topical corticosteroids for herpes simplex stromal keratitis","volume":"101","author":"Wilhelmus","year":"1994","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ophtha.2021.12.004_bib24","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1097\/ICO.0000000000001781","article-title":"Management Algorithm for Fungal Keratitis: The TST (Topical, Systemic, and Targeted Therapy) Protocol","volume":"38","author":"Sharma","year":"2019","journal-title":"Cornea"},{"key":"10.1016\/j.ophtha.2021.12.004_bib25","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.1001\/jamaophthalmol.2016.4167","article-title":"Evidence-Based Treatment of Fungal Keratitis","volume":"134","author":"Schein","year":"2016","journal-title":"JAMA Ophthalmol"},{"key":"10.1016\/j.ophtha.2021.12.004_bib26","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1136\/bjo.87.10.1235","article-title":"A\u00a0randomised clinical trial comparing 2% econazole and 5% natamycin for the treatment of fungal keratitis","volume":"87","author":"Prajna","year":"2003","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.ophtha.2021.12.004_bib27","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1001\/archopht.1959.00940090549008","article-title":"Keratomycosis: a report of six cases","volume":"61","author":"Barsky","year":"1959","journal-title":"AMA Arch Ophthalmol"},{"key":"10.1016\/j.ophtha.2021.12.004_bib28","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1001\/archopht.124.6.923","article-title":"Use of higher medication concentrations in the treatment of acanthamoeba keratitis","volume":"124","author":"Mathers","year":"2006","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.ophtha.2021.12.004_bib29","doi-asserted-by":"crossref","first-page":"106","DOI":"10.4103\/2008-322X.163782","article-title":"Chlorhexidine monotherapy with adjunctive topical corticosteroids for acanthamoeba keratitis","volume":"10","author":"Rahimi","year":"2015","journal-title":"J\u00a0Ophthalmic Vis Res"},{"key":"10.1016\/j.ophtha.2021.12.004_bib30","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1007\/s00417-012-2152-z","article-title":"Comparison of contamination rates between preserved and preservative-free fluoroquinolone eyedrops","volume":"251","author":"Kim","year":"2013","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"10.1016\/j.ophtha.2021.12.004_bib31","series-title":"A\u00a0comparison of two treatment regimes for the treatment of fungal eye infections in East Africa. ISRCTN Registry","author":"Hoffman","year":"2021"}],"container-title":["Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0161642021009210?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0161642021009210?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T14:11:31Z","timestamp":1758982291000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0161642021009210"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5]]},"references-count":31,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2022,5]]}},"alternative-id":["S0161642021009210"],"URL":"https:\/\/doi.org\/10.1016\/j.ophtha.2021.12.004","relation":{},"ISSN":["0161-6420"],"issn-type":[{"value":"0161-6420","type":"print"}],"subject":[],"published":{"date-parts":[[2022,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Topical Chlorhexidine 0.2% versus Topical Natamycin 5% for the Treatment of Fungal Keratitis in Nepal","name":"articletitle","label":"Article Title"},{"value":"Ophthalmology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ophtha.2021.12.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 by the American Academy of Ophthalmology.","name":"copyright","label":"Copyright"}]}}